Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis
Welichem announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study. The objectives of the trial are to evaluate the efficacy of the creams (0.5% and 1.0% WBI-1001) in comparison to the vehicle and also to evaluate the safety and tolerability of the creams in patients with atopic dermatitis.
The study is being conducted at three centers across Canada. It is planned that 150 patients will be enrolled in the trial that is anticipated to be concluded in 6 to 9 months.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Heptares enters a research and drug discovery collaboration with Juntendo University

Bacterial protein structure could aid development of new antibiotics
List_of_subjects_in_Gray's_Anatomy:_VI._The_Arteries
Compound identified that protects against neurodegeneration
Stem cells help researchers peg rabies resistance
Charley_horse
DxS Appoints David Jackson as Vice President of Business Development and Licensing
Melinda_Gates
SYGNIS strengthens IP position in the treatment of acute stroke with AX200 in the US
Merck Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Researchers optimizing progesterone for brain injury treatment - New approaches include adding vitamin D and using water-soluble analogues
